ArticleFrontiers in pharmacology2021

Cost-Effectiveness of First-Line Versus Second-Line Pembrolizumab or Chemotherapy in Patients With Microsatellite-Instability-High/Mismatch Repair-Deficient Advanced Colorectal Cancer.

Tan Chongqing et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.